-
DE
BA.3.2 is a subvariant of the Omicron lineage of the SARS-CoV-2 virus. It is part of the ongoing evolution of the coronavirus and is monitored by health authorities worldwide.
Regular tips about health Regular tips about health Add as Preferred SourceBA.3.2 is a subvariant of the Omicron lineage of the SARS-CoV-2 virus. It is part of the ongoing evolution of the coronavirus and is monitored by health authorities worldwide.
BA.3.2 is a subvariant within the Omicron lineage (B.1.1.529) of SARS-CoV-2, the virus responsible for COVID-19. The Omicron lineage encompasses numerous sublineages, including BA.1, BA.2, BA.3, BA.4, and BA.5, along with their further branches. BA.3.2 is one of these downstream sublineages identified as part of the continuous genetic evolution of the virus.
The BA.3.2 variant descends from the BA.3 sublineage, which is itself part of the broader Omicron family. Naming follows international nomenclature systems such as Pango, used for the systematic classification of SARS-CoV-2 lineages. BA.3 and its subvariants appeared in significantly lower case numbers compared to BA.1 and BA.2 and did not achieve dominant epidemiological significance.
Like other Omicron sublineages, BA.3.2 carries characteristic mutations in the spike protein, which is responsible for the binding of the virus to human cells. These mutations can influence transmissibility, immune evasion (the ability to escape an existing immune response), and disease severity.
Symptoms caused by BA.3.2 and related Omicron sublineages are similar to those of other Omicron variants:
Severe disease with pneumonia is less common with Omicron sublineages compared to earlier variants but can still occur in immunocompromised individuals, the elderly, and those with underlying health conditions.
Transmission of BA.3.2 occurs, as with all SARS-CoV-2 variants, primarily through aerosols and droplets released when an infected person speaks, coughs, or sneezes. Close contact in enclosed, poorly ventilated spaces significantly increases the risk of transmission.
Diagnosis of a COVID-19 infection caused by BA.3.2 follows the same methods used for all variants:
There is no treatment specific to BA.3.2. Management follows general COVID-19 treatment standards:
Available COVID-19 vaccines continue to provide meaningful protection against severe disease, including from Omicron sublineages such as BA.3.2. Regular booster vaccinations, updated to reflect circulating variants, are recommended by health authorities such as the WHO and national public health agencies.
BA.3.2 did not achieve dominant spread compared to other Omicron sublineages such as BA.2 or BA.5. Nevertheless, continuous surveillance by national and international health authorities remains essential to detect new variants early and respond swiftly to any changes in disease severity or vaccine effectiveness.
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Average rating of 4.97 out of 5 stars
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
Average rating of 4.85 out of 5 stars
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
Average rating of 4.86 out of 5 stars
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
Average rating of 4.94 out of 5 stars
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.